{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:42:57Z","timestamp":1784691777101,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T00:00:00Z","timestamp":1370563200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40264-013-0070-6","type":"journal-article","created":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T03:54:23Z","timestamp":1370490863000},"page":"681-686","source":"Crossref","is-referenced-by-count":11,"title":["Stevens\u2013Johnson Syndrome\/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk?"],"prefix":"10.1007","volume":"36","author":[{"given":"Cynthia","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Sidoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia H.","family":"Kardaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mockenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Creamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Dunant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,7]]},"reference":[{"key":"70_CR1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272\u20138.","journal-title":"N Engl J Med"},{"key":"70_CR2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","volume":"7","author":"M Mockenhaupt","year":"2011","unstructured":"Mockenhaupt M. The current understanding of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7:803\u201313.","journal-title":"Expert Rev Clin Immunol"},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","volume":"49","author":"B Rzany","year":"1996","unstructured":"Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49:769\u201373.","journal-title":"J Clin Epidemiol"},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","volume":"58","author":"J Schneck","year":"2008","unstructured":"Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"70_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","volume":"27","author":"A Oplatek","year":"2006","unstructured":"Oplatek A, Brown K, Sen S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27:26\u201333.","journal-title":"J Burn Care Res"},{"key":"70_CR6","volume-title":"Monitoring and assessment of adverse drug effects","year":"1986","unstructured":"Shapiro S, Dunne J, Kaufman D, editors. Monitoring and assessment of adverse drug effects. Geneva: CIOMS\/WHO; 1986."},{"key":"70_CR7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"JC Roujeau","year":"1995","unstructured":"Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600\u20137.","journal-title":"N Engl J Med"},{"key":"70_CR8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"M Mockenhaupt","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, et al. Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35\u201344.","journal-title":"J Invest Dermatol"},{"key":"70_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis. Clin Pharmacol Ther. 2010;88:60\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"70_CR10","unstructured":"Arzneimittelinformation. Innsbruck: MedEval GmbH Ed; 2009."},{"key":"70_CR11","unstructured":"Vidal Ed. Issy les Moulineaux: Vidal; 2009."},{"key":"70_CR12","unstructured":"Rote list. Frankfurt: Rote Liste\u00ae Service-GmbH Ed; 2009."},{"key":"70_CR13","unstructured":"Farmacotherapeutisch Kompas 2009, ed. AC van Loenen. Diemen: College voor zorgverzekeringen (CVZ); 2008."},{"key":"70_CR14","unstructured":"British National Formulary. London: BMJ Group & Pharmaceutical Press; 2009."},{"key":"70_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330903427969","volume":"9","author":"WH Chung","year":"2010","unstructured":"Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf. 2010;9:15\u201321.","journal-title":"Expert Opin Drug Saf"},{"key":"70_CR16","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"70_CR17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99\u2013107.","journal-title":"Pharmacogenet Genomics"},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","volume":"6","author":"E Genin","year":"2011","unstructured":"Genin E, Schumacher M, Roujeau JC, et al. Genome-wide association study of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52.","journal-title":"Orphanet J Rare Dis"},{"key":"70_CR19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/BCR.0b013e3181848bb1","volume":"29","author":"FW Endorf","year":"2008","unstructured":"Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29:706\u201312.","journal-title":"J Burn Care Res"},{"key":"70_CR20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","volume":"136","author":"I Garcia-Doval","year":"2000","unstructured":"Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323\u20137.","journal-title":"Arch Dermatol"},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/DBP.0b013e31817bd7c9","volume":"29","author":"A Cheung","year":"2008","unstructured":"Cheung A, Sacks D, Dewa CS, et al. Pediatric prescribing practices and the FDA black-box warning on antidepressants. J Dev Behav Pediatr. 2008;29:213\u20135.","journal-title":"J Dev Behav Pediatr"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","volume":"170","author":"ER Dorsey","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170:96\u2013103.","journal-title":"Arch Intern Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-013-0070-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0070-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:30Z","timestamp":1559490090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-013-0070-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,7]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s40264-013-0070-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,7]]}}}